Latest news

• FDA accepts priority review for Merck’s antibiotic combo Recarbrio

  The  regimen combines Merck’s imipenem/cilastatin duo – sold as Primaxin as a broad-spectrum antibiotic – with a new beta lactamase inhibitor called relebactam that is designed to restore the susceptibility

• Merck preps regulatory filings for much-needed antibiotic combo

  The regimen combines Merck’s own Primaxin with new beta lactamase inhibitor relebactam. ... Merck is also carrying out a phase III trial comparing the relebactam regimen with piperacillin/tazobactam, another widely-used antibiotic for hospital-acquired

• AZ gets EU green light for new antibiotic Zavicefta

  Meanwhile, Merck &Co is also working on a beta lactamase inhibitor called relebactam, and recently started a phase III programme looking at the drug in combination with imipenem.

• Merck starts pivotal trials of new antibiotic combination

  Continues testing after positive phase II results for relebactam addition . After positive phase II results, Merck &Co has decided to take a novel antibiotic into phase III testing. ... The first is comparing treatment with relebactam/imipenem to

• Merck prepares filings for Clostridium antibody

  tazobactam). Merck also has relebactam (MK-7655) in mid-stage trials as an intravenous treatment for acute bacterial infections.